Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix Presents Data from a Preclinical Study of Intravenous Brincidofovir at AAPS

DURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, ...
November 09, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Upcoming Investor Conferences

DURHAM, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle...
November 07, 2016 07:00 ET | Source: Chimerix, Inc.

Chimerix Announces Third Quarter 2016 Financial Results

- Brincidofovir IV Single and Multiple Dose Data Expected to Report Out in 2017 - - Comparative Adenovirus Trial with Oral Brincidofovir Expected to Start in 2017 - - CMX521 for Norovirus Advancing...
October 31, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016

DURHAM, N.C., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will...
October 27, 2016 16:01 ET | Source: Chimerix, Inc.

Chimerix Announces Presentation at IDWeek™ of Detailed 24-Week Results from AdVise Trial of Brincidofovir for the Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Recipients

– Results Show Early Virologic Response Associated with Better Overall Survival – DURHAM, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing...
September 06, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at the Morgan Stanley Global Healthcare Conference

DURHAM, N.C., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle...
August 08, 2016 07:30 ET | Source: Chimerix, Inc.

Chimerix Announces Second Quarter 2016 Financial Results

- European Commission Granted Orphan Drug Designation for Brincidofovir for the Treatment of Adenovirus - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Aug. 08, 2016 (GLOBE NEWSWIRE)...
August 01, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016

DURHAM, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it...
June 07, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix to Participate in Panel on North Carolina’s Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium

DURHAM, N.C., June 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M....
May 09, 2016 07:30 ET | Source: Chimerix, Inc.

Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results

- Maintains strong financial position with $314.5 million in capital at quarter end - - Company to hold conference call at 8:30am ET today - DURHAM, N.C., May 09, 2016 (GLOBE NEWSWIRE) --...